Literature DB >> 26732599

Association Between Circulating Copeptin Level and Mortality Risk in Patients with Intracerebral Hemorrhage: a Systemic Review and Meta-Analysis.

Ruoyu Zhang1, Jin Liu2, Ying Zhang3, Qiang Liu2, Tianlang Li2, Lei Cheng4.   

Abstract

Copeptin has been identified as a biomarker of disease severity and is associated with mortality risk in several common diseases. This study sought to determine the association between circulating copeptin level and mortality risk in patients with intracerebral hemorrhage. PubMed, Web of Science, and Wanfang Medicine Database were searched for studies assessing the association between circulating copeptin level and mortality risk in patients with intracerebral hemorrhage. The pooled hazard ratio (HR) of mortality was calculated and presented with 95 % confidence interval (95 % CI). Data from 1332 intracerebral hemorrhage patients were derived from 9 studies. Meta-analysis showed that intracerebral hemorrhage patients with poor prognosis had much higher copeptin levels than those survivors (standardized mean difference = 1.68, 95 % CI 1.26-2.11, P < 0.00001). Meta-analysis of 8 studies with HRs showed that high circulating copeptin level was associated with higher risk of mortality in patients with intracerebral hemorrhage (HR = 2.42, 95 % CI 1.60-3.65, P < 0.0001). Meta-analysis of 6 studies with adjusted HRs showed that high circulating copeptin level was independently associated with higher risk of mortality in patients with intracerebral hemorrhage (HR = 1.67, 95 % CI 1.26-2.22, P = 0.0003). Our study suggests that there is an obvious association between circulating copeptin level and mortality in patients with intracerebral hemorrhage. High circulating copeptin level is independently associated with higher risk of mortality in patients with intracerebral hemorrhage.

Entities:  

Keywords:  Copeptin; Intracerebral hemorrhage; Meta-analysis; Mortality

Mesh:

Substances:

Year:  2016        PMID: 26732599     DOI: 10.1007/s12035-015-9626-z

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  39 in total

1.  Prediction of all-cause mortality with copeptin in cardio-cerebrovascular patients: A meta-analysis of prospective studies.

Authors:  Hao Sun; Ting Sun; Bing Ma; Bo-wen Yang; Yao Zhang; Dong-hui Huang; Jing-pu Shi
Journal:  Peptides       Date:  2015-04-04       Impact factor: 3.750

2.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

3.  Traumatic brain injury results in a concomitant increase in neocortical expression of vasopressin and its V1a receptor.

Authors:  C L Pascale; J Szmydynger-Chodobska; J E Sarri; A Chodobski
Journal:  J Physiol Pharmacol       Date:  2006-11       Impact factor: 3.011

4.  Operating characteristics of a rank correlation test for publication bias.

Authors:  C B Begg; M Mazumdar
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

Review 5.  Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology.

Authors:  Davide Bolignano; Aderville Cabassi; Enrico Fiaccadori; Ezio Ghigo; Renato Pasquali; Andrea Peracino; Alessandro Peri; Mario Plebani; Antonio Santoro; Fabio Settanni; Carmine Zoccali
Journal:  Clin Chem Lab Med       Date:  2014-10       Impact factor: 3.694

Review 6.  Serum biomarkers of spontaneous intracerebral hemorrhage induced secondary brain injury.

Authors:  Andrew S Brunswick; Brian Y Hwang; Geoffrey Appelboom; Richard Y Hwang; Matthew A Piazza; E Sander Connolly
Journal:  J Neurol Sci       Date:  2012-08-02       Impact factor: 3.181

Review 7.  Plasmatic markers in hemorrhagic stroke.

Authors:  I C Marginean; D M Stanca; V Vacaras; O Soritau; M Margiean; D F Muresanu
Journal:  J Med Life       Date:  2011-05-25

8.  Circulating levels of copeptin predict outcome in patients with pulmonary arterial hypertension.

Authors:  Nils P Nickel; Ralf Lichtinghagen; Heiko Golpon; Karen M Olsson; Korbinian Brand; Tobias Welte; Marius M Hoeper
Journal:  Respir Res       Date:  2013-11-19

9.  Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study.

Authors:  Martin Möckel; Julia Searle; Christian Hamm; Anna Slagman; Stefan Blankenberg; Kurt Huber; Hugo Katus; Christoph Liebetrau; Christian Müller; Reinhold Muller; Philipp Peitsmeyer; Johannes von Recum; Milos Tajsic; Jörn O Vollert; Evangelos Giannitsis
Journal:  Eur Heart J       Date:  2014-04-30       Impact factor: 29.983

10.  Risk stratification in emergency patients by copeptin.

Authors:  Kasper Iversen; Jens P Gøtze; Morten Dalsgaard; Henrik Nielsen; Søren Boesgaard; Morten Bay; Vibeke Kirk; Olav W Nielsen; Lars Køber
Journal:  BMC Med       Date:  2014-05-16       Impact factor: 8.775

View more
  4 in total

Review 1.  Copeptin as a Diagnostic and Prognostic Biomarker in Cardiovascular Diseases.

Authors:  Danni Mu; Jin Cheng; Ling Qiu; Xinqi Cheng
Journal:  Front Cardiovasc Med       Date:  2022-07-04

2.  Screening of gestational diabetes mellitus in early pregnancy by oral glucose tolerance test and glycosylated fibronectin: study protocol for an international, prospective, multicentre cohort trial.

Authors:  E A Huhn; T Fischer; C S Göbl; M Todesco Bernasconi; M Kreft; M Kunze; A Schoetzau; E Dölzlmüller; W Eppel; P Husslein; N Ochsenbein-Koelble; R Zimmermann; E Bäz; H Prömpeler; E Bruder; S Hahn; I Hoesli
Journal:  BMJ Open       Date:  2016-10-12       Impact factor: 2.692

3.  Prognostic role of copeptin with all-cause mortality after heart failure: a systematic review and meta-analysis.

Authors:  Peng Zhang; Xiaomei Wu; Guangxiao Li; Hao Sun; Jingpu Shi
Journal:  Ther Clin Risk Manag       Date:  2017-01-05       Impact factor: 2.423

4.  Association between Serum Copeptin and Stroke in Rural Areas of Northern China: A Matched Case-Control Study.

Authors:  Hao Sun; Donghui Huang; Hailong Wang; Bo Zhou; Xiaomei Wu; Bing Ma; Jingpu Shi
Journal:  Dis Markers       Date:  2018-10-04       Impact factor: 3.434

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.